CSBR vs INCY · P/E 16, rev $59.4M vs P/E 14, rev $5.14B
Champions Oncology Inc (CSBR) versus Incyte Corporation (INCY) — a side-by-side from cached financials, not a winner call.
Champions Oncology Inc (CSBR) is a biotechnology company listed on US.
Incyte Corporation (INCY) is a biotechnology company listed on US.
Latest reported CSBR revenue for 2026-04-30 was $59.4M. Net income was -$1.2M. Revenue was up 4.4% from 2025-04-30 to 2026-04-30. CSBR currently screens at market cap $99.8M and trailing P/E 16.0.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. Revenue was up 21.2% from 2024-12-31 to 2025-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
CSBR currently screens at market cap $99.8M and trailing P/E 16.0. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Not investment advice. Open the CSBR and INCY stock pages for the full models.
Not investment advice.